Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell Patents (Class 424/152.1)
  • Publication number: 20100291099
    Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 20A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 17, 2010
    Publication date: November 18, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Maria A. Glucksmann, Mark J. Williamson, Fong-Ying Tsai, Laura A. Rudolph-Owen, Rosanna Kapeller-Libermann, Rachel E. Meyers, Lillian Wei-Ming Chiang, John Joseph Hunter
  • Publication number: 20100291101
    Abstract: The present invention provides the novel anti-IRC85 monoclonal antibody specifically binding with IRC85 and it showed potent effect in removing the infected/phagocytosed bacteria from THP-I, a monocytic cell that expresses human IRC85 and is infected with Listeria monocytogenes or WR-tubercle bacillus. Accordingly, it can be useful as a medicament and health care food in the prevention and treatment of tuberculosis disease and enteritis disease.
    Type: Application
    Filed: April 24, 2008
    Publication date: November 18, 2010
    Applicant: BIO-SUPPORT CO., LTD.
    Inventor: Byoung Se Kwon
  • Patent number: 7833530
    Abstract: The present invention is directed to antibodies and binding fragments thereof, which bind with high affinity and specificity to human P-selectin glycoprotein ligand 1 (PSGL-1) and which block both selectin and chemokine binding to PSGL-1 expressed on leukocytes, lymphocytes and endothelial cells and thus which inhibit migration and/or rolling of these cells and to methods for screening for such antibodies and binding fragments thereof and to methods of therapeutic use thereof.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: November 16, 2010
    Assignee: Selexys Pharmaceuticals Corporation
    Inventors: Richard Alvarez, Scott Rollins
  • Publication number: 20100284969
    Abstract: The disclosure provides a drug composition formulated for inhalation comprising a conjugate of a surface active agent and a pulmonary active drug. The surface active agent has an affinity for the human alveolar/gas interface and comprises at least a portion of a mammalian lung surfactant of a mimic thereof. The disclosure also provides a method of treating a subject suffering from or at risk of suffering from a lung disease comprising administering to the subject a conjugate comprising a drug for lung treatment and a surface active agent by inhalation in an amount effective to induce a drug effect in the lungs.
    Type: Application
    Filed: June 4, 2008
    Publication date: November 11, 2010
    Inventor: Frank Guarnieri
  • Publication number: 20100278836
    Abstract: Low levels of antibodies reactive with a PAF-conjugate are related to an increased risk of developing cardiovascular diseases. Thus, compositions and methods of diagnosis and therapy for cardiovascular diseases are provided.
    Type: Application
    Filed: October 29, 2008
    Publication date: November 4, 2010
    Applicant: ATHERA BIOTECHNOLOGIES AB
    Inventors: Hans Grönlund, Johan Frostegard, Ingrid Dahlbom
  • Patent number: 7824680
    Abstract: The invention provides methods for detecting and inhibiting angiogenesis, endothelial cell adhesion, and endothelial cell migration using agents which inhibit the specific binding of integrin ?4?1 to one or more of its ligands. The invention further provides methods for screening test compounds for their ability to inhibit angiogenesis, endothelial cell adhesion, or endothelial cell migration by employing agents which inhibit the specific binding of integrin ?4?1 to one or more of its ligands. The invention additionally relates to methods for isolating endothelial progenitor cells which express integrin ?4?1. The methods of the invention are useful in, for example, diagnosing and inhibiting pathological conditions that are associated with angiogenesis, endothelial cell adhesion, and/or endothelial cell migration.
    Type: Grant
    Filed: August 1, 2002
    Date of Patent: November 2, 2010
    Assignee: The Regents of the University of California
    Inventor: Judith A. Varner
  • Patent number: 7824684
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: November 2, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
  • Patent number: 7824683
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: November 2, 2010
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Patent number: 7825223
    Abstract: The present application provides methods of purifying A? binding proteins having a Fc region, for example, anti-A? antibodies or antibody fusions, by adsorbing the A? binding protein to a Fc binding agent, such as, for example, Protein A or Protein G, followed by a wash with a divalent cation salt buffer to remove impurities and subsequent recovery of the adsorbed A? binding protein. The present application also features methods of eluting the purified A? binding protein as well as the incorporation of the methods within a purification train. Kits comprising components for carrying out the methods and instructions for use are also provided.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: November 2, 2010
    Assignees: Janssen Alzheimer Immunotherapy, Wyeth LLC
    Inventors: Ranganathan Godavarti, Timothy Iskra
  • Publication number: 20100260764
    Abstract: The present invention relates to compositions and methods for detecting and inhibiting squamous cell carcinoma using agents that target the laminin 332 ?2 processed region polypeptide.
    Type: Application
    Filed: August 28, 2008
    Publication date: October 14, 2010
    Inventor: M. Peter Marinkovich
  • Patent number: 7812133
    Abstract: The invention provides anti-OX40L antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: October 12, 2010
    Assignee: Genentech, Inc
    Inventor: Flavius Martin
  • Patent number: 7807167
    Abstract: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: October 5, 2010
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Julie Taylor, Theodore A. Yednock
  • Patent number: 7807165
    Abstract: Monoclonal antibody 9TL and antibodies derived from 9TL directed against amyloid-beta peptide and methods of using same for diagnosing and treatment of Alzheimer's disease and A? peptide associated diseases are described. Methods of using antibodies directed against amyloid-beta peptide having impaired effector function for treatment of Alzheimer's disease and A? peptide associated diseases are also described.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: October 5, 2010
    Assignee: Rinat Neuroscience Corp.
    Inventors: Arnon Rosenthal, Jaume Pons, Wei-Hsien Ho, Jan Markus Grimm
  • Publication number: 20100247525
    Abstract: The present invention provides compositions and methods for preventing and inhibiting anthrax lethality. The present invention relates to protect a subject from anthrax lethality by presensitizing a subject prior to anthrax infection. The present invention further provides compositions and methods for enhancing the innate system to inhibit anthrax-associated lethality. The invention further provides compositions and methods for preventing and inhibiting lethality due to infection regulated via a TNF-? pathway.
    Type: Application
    Filed: May 8, 2007
    Publication date: September 30, 2010
    Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Edward N. Martin, JR., W. Michael Scheld
  • Publication number: 20100247530
    Abstract: The present invention provides compositions and methods for preventing and treating presbycusis. In particular, the present invention provides compositions and methods for preventing and treating presbycusis by inhibiting Bak.
    Type: Application
    Filed: March 19, 2010
    Publication date: September 30, 2010
    Applicant: MARINE BIO CO., LTD.
    Inventors: Shinichi Someya, Tomas A. Prolla
  • Publication number: 20100239570
    Abstract: A monoclonal antibody against beta-amyloid (ABeta) peptide is provided with unique immunological and biological properties useful in the immunotherapy of Alzheimer's disease. In addition, pharmaceutical compositions and kits comprising such antibody and mimics thereof in the treatment of neurological disorders such as Alzheimer's disease are described.
    Type: Application
    Filed: September 15, 2008
    Publication date: September 23, 2010
    Inventor: Roger Nitsch
  • Publication number: 20100239591
    Abstract: The invention relates to a novel peptide, polypeptide or monoclonal antibody for use in the treatment of conditions characterised by elevated levels of ?-amyloid (A? 39-43 amino acid peptide) in a subject, especially Alzheimer's Disease. The invention particularly relates to an amyloid precursor protein (APP)-binding polypeptide which, when administered outside an APP-expressing cell, reduces the release of A? 39-43 by the cell.
    Type: Application
    Filed: October 23, 2008
    Publication date: September 23, 2010
    Inventors: Emma Jane Kidd, Janet Erly Liddell, Rhian Sara Thomas
  • Publication number: 20100233171
    Abstract: We describe a method to diagnose and treat an animal, preferably a human, suffering from a condition, typically cancer, that would benefit from a stimulation of apoptosis in tumour cells and including screening methods to identify new chemotherapeutic agents.
    Type: Application
    Filed: November 20, 2009
    Publication date: September 16, 2010
    Inventor: XIN LU
  • Publication number: 20100233162
    Abstract: The present invention relates to a composition comprising IgY antibodies against at least two different fungi, the use of the composition for the preparation of a pharmaceutical especially for prophylaxis and/or therapy of all kinds of fungal infections, such as conditions caused by organisms belonging to the Candida genus or Aspergillus genus, especially of fungi that are less sensitive to antimycotica and a diagnotstic method using the IgY antibodies. Further it relates to immunisation of birds with a combination of at least two different species of fungi to the Candida genus or Aspergillus genus and a diagnostic method for fungi. It also relates to relates to a novel method for treatment and/or prophylaxis of fungal infections, especially infections by fungi which have lowered sensitivity or resistance to antimycotics. The method is both safe and effective.
    Type: Application
    Filed: August 28, 2008
    Publication date: September 16, 2010
    Applicant: Bengt AGERUP
    Inventors: Anders Larsson, Hans Kollberg
  • Publication number: 20100226927
    Abstract: The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment and tolerance.
    Type: Application
    Filed: November 2, 2007
    Publication date: September 9, 2010
    Inventors: Irving L. Weissman, Agnieszka Czechowicz, Deepta Bhattacharya, Daniel Kraft
  • Publication number: 20100226928
    Abstract: Anti-sclerostin antibodies are formulated as lyophilisates. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 25 mg/ml. The lyophilisate may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Application
    Filed: March 5, 2010
    Publication date: September 9, 2010
    Inventor: Bhas A. DANI
  • Publication number: 20100215712
    Abstract: A blood vessel metal stent coating of amidoglucosan polysaccharide loaded with antibody comprises carrier material composed of chitosan and inartificial degradable acidic amidoglucosan polysaccharide and the effective dose of CD133 antibody loaded in the carrier material. The blood vessel metal stent coating is manufactured with self-assemble method to fix the CD133 antibody in the carrier material of the coating. The coating has good biocompatibility, water retention property, flexibility, flush resistance and bio-stability, and can specifically capture the vascular endothelial progenitor cells in human peripheral blood, and differentiate into vascular endothelial cells. The process would accelerate endothelialization to repair injured vessel caused and prevent restenosis and thrombosis efficiently.
    Type: Application
    Filed: October 10, 2008
    Publication date: August 26, 2010
    Inventors: Shixuan Zhang, Jinghan Sui, Hong Zhao, Dazhi Yang
  • Publication number: 20100209417
    Abstract: Provided is an antibody that selectively binds to an epitope formed by residues 1-11 of A? in an A? oligomer, a method comprising using the antibody to treat a disease characterized by such an A? amyloid deposit in a patient, and kits comprising same.
    Type: Application
    Filed: November 21, 2006
    Publication date: August 19, 2010
    Inventors: Virginia M.Y. Lee, Edward B. Lee, John Q. Trojanowski
  • Patent number: 7776311
    Abstract: The present invention provides compounds of the formula X—R1-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5; or R1(X)-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5, in which X is a hard acid cation chelator, a soft acid cation chelator or Ac-, R1, R2 and R3 are independently selected from a covalent bond or one or more D-amino acids that can be the same or different, Y is a hard acid cation chelator, a soft acid cation chelator or absent, Z is a hard acid cation chelator, a soft acid cation chelator or absent, and A and B are haptens or hard acid cation chelators and can be the same or different, and R4 and R5 are independently selected from the group consisting of hard acid cation chelators, soft acid cation chelators, enzymes, therapeutic agents, diagnostic agents and H. The present invention also provides methods of using these compounds and kits containing the compounds.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: August 17, 2010
    Assignee: Immunomedics, Inc.
    Inventors: William J. McBride, David M. Goldenberg
  • Publication number: 20100203044
    Abstract: Methods and compositions comprising DR6 antagonists for use in treating neurological disorders, including Alzheimer's disease, are provided. The DR6 antagonists include anti-APP antibodies, anti-DR6 antibodies, DR6 immunoadhesins and DR6 variants (and fusion proteins thereof) which enhance growth, regeneration or survival of mammalian neuronal cells or tissue.
    Type: Application
    Filed: December 21, 2007
    Publication date: August 12, 2010
    Inventors: Anatoly Nikolaev, Marc Tessier-Lavigne
  • Patent number: 7771722
    Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A?40, A?42, their ratio, or their rate of entry following administration of antibodies that sequester A?. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: August 10, 2010
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul
  • Publication number: 20100196392
    Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.
    Type: Application
    Filed: July 17, 2009
    Publication date: August 5, 2010
    Applicant: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Norihiko SHIRAISHI, Akiko Furuya, Hiroe Toki, Hiroshi Ando, Masayo Suzuki, Tsuguo Kubota
  • Publication number: 20100196374
    Abstract: The disclosure relates to OX-2/CD200 (herein referred to as CD200) antibodies and methods of treating autoimmune disease.
    Type: Application
    Filed: July 25, 2008
    Publication date: August 5, 2010
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventor: Yi Wang
  • Publication number: 20100196393
    Abstract: There are disclosed agents that inhibit Blood Brain Barrier Proteins (BBBP). Such agents are useful in controlling agents entering and exiting the CNS. This allows for drugs to be more effective and/or allowing side effects of the drugs to be lowered.
    Type: Application
    Filed: April 23, 2008
    Publication date: August 5, 2010
    Applicant: ST. LOUIS UNIVERSITY
    Inventors: William A. Banks, Vijaya B. Kumar, Thomas Darling, Robert Clayton
  • Patent number: 7763250
    Abstract: Antibodies directed to the C-terminal side of ?-amyloid peptide and methods of using these antibodies for diagnosing and treatment of Alzheimer's disease and A? peptide associated diseases are described.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: July 27, 2010
    Assignee: Rinat Neuroscience Corp.
    Inventors: Arnon Rosenthal, Jaume Pons, Wei-Hsien Ho
  • Patent number: 7754212
    Abstract: Oral, topical and injectable contraceptives, which are based on sperm protein 22 kDa (SP22) polypeptides and antibodies and infertility diagnostics are provided.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: July 13, 2010
    Assignee: U.S. Environmental Protection Agency
    Inventor: Gary R. Klinefelter
  • Publication number: 20100172905
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Application
    Filed: July 1, 2009
    Publication date: July 8, 2010
    Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
    Inventors: KEVIN J. TRACEY, HAICHAO WANG
  • Publication number: 20100172902
    Abstract: A method for treating a VCAM-1 mediated disease comprising administering a therapeutically effective amount of a monoclonal antibody to a patient in need thereof. The monoclonal antibody specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1). The monoclonal antibody comprises(a) a light chain CDR 1 region defined by SEQ ID NO:5, a light chain CDR 2 region defined by SEQ ID NO:6, and a light chain CDR 3 region defined by SEQ ID NO:7, and (b) a heavy chain CDR 1 region defined by SEQ ID NO:8, a heavy chain CDR 2 region defined by SEQ ID NO:.9 or 11, and a heavy chain CDR 3 region defined by SEQ ID NO:10 or 12.
    Type: Application
    Filed: December 10, 2009
    Publication date: July 8, 2010
    Applicant: HANWHA CHEMICAL CORPORATION
    Inventors: Junho CHUNG, Eun Kyung RYU, Ji Eun LEE, Sukmook LEE
  • Publication number: 20100172913
    Abstract: An objective of the present invention is to provide methods for treating or preventing fibrotic diseases, which are based on the novel finding that fibrosis is suppressed by administering ER-TR7 to a subject.
    Type: Application
    Filed: June 6, 2008
    Publication date: July 8, 2010
    Inventor: Hiroyuki Yoneyama
  • Patent number: 7744871
    Abstract: The present invention is related to the field of immunology and more specifically to cancer immunotherapy, particularly with immunotherapeutic combinations and treatment methods to prevent tumor cell growth and/or to eliminate those cells. The methods described in the present invention are based on the blockade of receptors with protein kinase activity in tyrosine residues (Receptor Tyrosine Kinases, RTK) and of ligands for those receptors. Immunotherapeutic combinations are described that cause the blockade of RTK receptors and/or their ligands, by means of a combination of passive and active immunotherapy. The referenced procedures can be applied to patients in different clinical stages with tumors of epithelial origin that over-express those receptors. The combination of active and passive immunotherapy can be simultaneous or sequential independent of whether the therapeutic procedure will be used in patients with advanced disease or as adjuvant therapy.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: June 29, 2010
    Assignee: Centro De Inmunologia Molecular
    Inventors: Rolando Pérex Rodriguez, Gisela Maria González Marinello, Tania Crobet Ramos, Irene Beausoleil Del Gado
  • Patent number: 7744888
    Abstract: Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: June 29, 2010
    Assignee: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung-Hsiun Wu, Pei-Ling Hsu
  • Publication number: 20100158912
    Abstract: Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.
    Type: Application
    Filed: September 11, 2009
    Publication date: June 24, 2010
    Applicant: INSTITUT PASTEUR
    Inventors: Marie-Lise Gougeon, Hela Saidi, Marie-Therese Melki, Beatrice Poirier-Beaudoin, Valerie Seffer
  • Publication number: 20100136002
    Abstract: We have discovered that LRG-47 (also called p47 GTPase), plays a central role in the pathogenesis of multiple sclerosis, and that inhibition of LRG-47 activity by anti-LRG-47 antibodies or of LRG-47 expression by siRNA dramatically reduce the pathology and symptoms of multiple sclerosis. Certain embodiments of the invention are directed to the therapeutic use of anti-LRG-47 antibodies (mouse or rabbit or other antibodies that are humanized or human antibodies to LRG-47, preferably antibodies made against human LRG-47) or siRNA or antisense nucleotides that specifically hybridize with the gene or mRNA or cDNA encoding human LRG-47 to treat or prevent multiple sclerosis and other autoimmune diseases that are T-cell-mediated. Other embodiments are directed to methods for the diagnosis of multiple sclerosis or to determining the aggressiveness of multiple sclerosis by determining the amount of human LRG-47 or LRG-47 mRNA in a biological sample from the patient.
    Type: Application
    Filed: May 1, 2008
    Publication date: June 3, 2010
    Inventor: Shi Du Yan
  • Publication number: 20100135996
    Abstract: The present invention relates to monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II) and their use for treating and diagnosing cancer diseases, such as ovarian cancers.
    Type: Application
    Filed: October 31, 2007
    Publication date: June 3, 2010
    Inventors: Isabelle Teulon, André Pelegrin
  • Publication number: 20100136001
    Abstract: Disclosed herein are methods for treating a vascular inflammatory disorder or endothelial cell disorder using inhibitor compounds that inhibit the expression or biological activity of Tie-1, Tie-1 endodomain, thrombin, VEGFR2, VEGFR2 endodomain, EphA2, and any of the cytokines or kinases that are upregulated by activation of Tie-1 or thrombin, as provided herein. Also disclosed are the use of combinations of inhibitor compounds or the use of an eNOS activator compound in combination with any one or more of the inhibitor compounds. Also disclosed are methods for inhibiting the pro-coagulant activity of thrombin using a Tie-1 or Tie-1 endodomain inhibitor compound or an EphA2 inhibitor compound. Methods for diagnosing and monitoring vascular inflammatory disorders or endothelial cell disorders that include the measurement of any of the polypeptides or nucleic acid molecules of the invention are also disclosed.
    Type: Application
    Filed: November 18, 2009
    Publication date: June 3, 2010
    Applicant: Beth Israel Deaconess Medical Center
    Inventors: Vikas P. Sukhatme, Chunkong Barden Chan
  • Publication number: 20100129376
    Abstract: Monoclonal antibodies immunospecific for osteopontin are disclosed. Also provided are therapeutic methods of use thereof for modulating osteopontin levels for the treatment of autoimmune disorders.
    Type: Application
    Filed: August 24, 2009
    Publication date: May 27, 2010
    Inventors: David T. Denhardt, Lawrence Steinman
  • Publication number: 20100129356
    Abstract: The present invention provides methods of using a DLL4 modulator to modulate vascular development. Furthermore, methods of treatment using DLL4 modulators, such as DLL4 antagonists, are provided.
    Type: Application
    Filed: July 2, 2009
    Publication date: May 27, 2010
    Applicant: GENENTECH, INC.
    Inventor: MINHONG YAN
  • Patent number: 7709611
    Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases including bone disorders, inflammatory diseases, neurological diseases, ocular diseases, renal diseases, pulmonary diseases and skin diseases are also disclosed.
    Type: Grant
    Filed: August 4, 2005
    Date of Patent: May 4, 2010
    Assignee: Amgen Inc.
    Inventors: Ji Li, Wenyan Shen, Hsieng Sen Lu, William Gleason Richards
  • Publication number: 20100092423
    Abstract: The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Autoimmune Diseases, particularly the Rheumatoid Arthritis.
    Type: Application
    Filed: December 24, 2007
    Publication date: April 15, 2010
    Applicant: CENTRO DE INMUNOLGÍA MOLECULAR
    Inventors: Jose Enrique Montero Casimiro, Angel Raimundo Casaco Parada, Zaima Mazorra Herrera, Ruby Alonao Ramirez, Rolando Perez Rodriguez
  • Publication number: 20100092467
    Abstract: Provided herein are compositions and methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. This in turn reduces or prevents tissue necrosis and death.
    Type: Application
    Filed: October 5, 2007
    Publication date: April 15, 2010
    Inventors: Jeffrey S. Isenberg, David D. Roberts, William A. Frazier
  • Patent number: 7691373
    Abstract: Nucleic acids encoding various lymphocyte cell proteins from mammalian, including primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: April 6, 2010
    Assignee: Schering Corporation
    Inventors: Jenny Valladeau, Odile Ravel, Elizabeth Esther Mary Bates, John Ford, Sem Saeland, Serge J. E. Lebecque
  • Publication number: 20100080811
    Abstract: Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.
    Type: Application
    Filed: November 3, 2009
    Publication date: April 1, 2010
    Inventors: JULIAN DAVIES, BRYAN EDWARD JONES, ANDREW IHOR KORYTKO, PAMELA JEAN MITCHELL, ROSAMUND CAROL SMITH, LINDA MAUREEN O'BRYAN (NEE TOBIAS), RONG WANG
  • Publication number: 20100074904
    Abstract: The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.
    Type: Application
    Filed: January 30, 2008
    Publication date: March 25, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Franz-Josef Schneider, Christian Becker, Tobias Bopp, Helmut Jonuleit, Edgar Schmitt
  • Patent number: 7666422
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: January 20, 2009
    Date of Patent: February 23, 2010
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Patent number: 7651689
    Abstract: This invention provides methods for treating infections in a subject which comprise administering to the subject an amount of a radiolabeled antibody effective to treat the infection, wherein the antibody specifically binds to the agent causing the infection. The invention also provides compositions and methods of making compositions comprising radiolabeled antibodies for the treatment of infections.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: January 26, 2010
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Ekaterina Dadachova, Arturo Casadevall, Antonio Nakouzi